Navigation Links
Study Raises New Questions About Cholesterol Drug Zetia
Date:11/16/2009

It was found less effective than extended-release niacin, or Niaspan

SUNDAY, Nov. 15 (HealthDay News) -- A new study raises more questions about ezetimibe (Zetia), a drug used by millions of Americans in tandem with statins to lower LDL, or "bad," cholesterol.

The trial, known as ARBITER-6 HALTS, was stopped early in June after it was discovered that LDL-cholesterol-lowering Zetia was less effective than extended-release niacin (Niaspan), which raises HDL, or "good," cholesterol levels, in reducing plaque build-up in the arteries.

Clinical trials are generally terminated early if a safety issue arises, less so when a measure of success is achieved.

The niacin combination also reduced the number of heart attacks and deaths.

"This trial provides a clear and undeniable statement on the superior clinical effectiveness of niacin over ezetimibe," study principal investigator Dr. Allen Taylor, director of Advanced Cardiovascular Imaging and the Lipid/Prevention Clinic at Washington Hospital Center in Washington, D.C., said at a Sunday afternoon news conference.

The study was funded by the pharmaceutical company Abbott Laboratories, which makes Niaspan, and Taylor and other study authors have received consulting fees from the company. Merck & Co. makes Zetia.

Taylor presented the findings at the American Heart Association's annual meeting in Orlando, Fla. The report was also released early online Nov. 16 in the New England Journal of Medicine.

"This trial showed the clear superiority of niacin over ezetimibe. I would say that the combination of LDL-lowering and HDL-increasing with niacin was associated with a greater regression of atherosclerosis," added Dr. John J.P. Kastelein, author of one of two editorials accompanying the paper. Kastelein is with the department of vascular medicine, Academic Medical Center, Meibergdreef, the Netherlands.

The current eviden
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PROVIDENCE, R.I. [Brown University] As Congress adjourns this ... bills senators will step over on their way out ... (SGR) Repeal and Medicare Provider Payment Modernization Act of ... JAMA Surgery , Dr. Eli Adashi recounts what he ... originally bipartisan bill. The perennial trouble with how Medicare ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Boston, MA (PRWEB) September 17, 2014 ... have partnered to create a monthly concert series, ... arts organization From the Top, America’s premier national ... classically-trained young musicians. Many of the young musicians ... the Top. , “Boston Children’s Museum is fortunate ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
(Date:9/17/2014)... 17, 2014 StartX , a ... companies raising rounds of funding at its Summer Demo ... investors and media, was the first such gathering held ... to the university. The presentations were delivered on an ... StartX-QB3 Labs, a 2,000 square foot life science facility ...
Breaking Medicine News(10 mins):Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6
... to present findings at AMCP Conference in AprilST. ... Prime Therapeutics (Prime) revealed a significant reduction in ... a retrospective drug utilization review (RetroDUR) program paired ... research was recently published in the American Journal ...
... healing time and pain reduction, , , TUESDAY, April 14 ... production of stem cells appears to "jump-start" the bone-healing ... as fast as young people,s, suggest preliminary results released ... University of Rochester Medical Center in New York gave ...
... Expects to qualify for 180 days of sole marketing ... MYL ) today confirmed that the company and its ... Roche Inc. in connection with the filing of an ... and Drug Administration (FDA) for Capecitabine Tablets, 150 mg ...
... Pearl of Wisdom to Help Prevent Cervical Cancer UPPER MARLBORO, Md., ... knows about and benefits from the tools - the Pap test, ... from this disease. That,s the message that the Pearl of Wisdom(TM) ... women to get - and share - in honor of Mother,s ...
... Versus 2008 First Quarter; , EPS was $1.26, Equal to ... Johnson (NYSE: JNJ ) today announced sales of ... of 7.2% as compared to the first quarter of 2008. ... was 6.0%. Domestic sales declined 5.0%, while international sales declined ...
... The American Federation for Medical Research (AFMR) today has ... sectors to take action against the crisis in U.S. ... major U.S. government agencies, corporations and leading academic institutions ... clinical research from advancing in America. This lack of ...
Cached Medicine News:Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 2Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 3Health News:Slow-Healing Bones May Get Boost From Drug 2Health News:Slow-Healing Bones May Get Boost From Drug 3Health News:Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment 2Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 2Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 3Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 4Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 2Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 3Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 4Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 5Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 6Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 7Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 8Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 9Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 10Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 11Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 12Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 13Health News:The American Federation for Medical Research Unites Top Leaders to Mitigate U.S. Crisis in Clinical Research 2
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... 2020 Summary GlobalData,s ... to 2020", provides key market data on the ... value, in millions of US dollars, volume (in ... market segments - Female Sterilization Devices (Transcervical Sterilization ...
(Date:9/17/2014)... 2014 BRIC Biopsy Devices Market Outlook to ... report, "BRIC Biopsy Devices Market Outlook to 2020", provides ... The report provides value, in millions of US dollars, ... within market segments - Biopsy Guns (Disposable and Reusable ... (Disposable and Reusable Fine Aspiration Needles) and Disposable Vacuum-Assisted ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new ... provides key market data on the BRIC Gynecological ... of US dollars, volume (in units) and average ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and ...
Breaking Medicine Technology:North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3BRIC Biopsy Devices Market Outlook to 2020 2BRIC Biopsy Devices Market Outlook to 2020 3BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3
... New data presented at annual American Transplant Congress ... R. Carreno, MD, and colleagues in,the Departments of ... -,Lawrence Miller School of Medicine have corroborated the ... in recipients of,kidney transplants using a regular laboratory ...
... 2 Medarex, Inc.,(Nasdaq: MEDX ) ... Phase 1,study of MDX-1106 (ONO-4538: development code ... anti-PD-1 antibody. Data presented from patients with,recurrent ... the safety,tolerability and pharmacokinetic profile of single-dose ...
Cached Medicine Technology:University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Standard Trephine...
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Long Handled Trephine...
Medicine Products: